InVitae Stock Forecast, Price & News

InVitae's stock was trading at $15.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NVTA shares have increased by 190.7% and is now trading at $46.08.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InVitae in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for InVitae.

InVitae is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for InVitae.

InVitae will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

InVitae Corp (NYSE:NVTA) released its earnings results on Tuesday, August, 4th. The medical research company reported ($0.77) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.62) by $0.15. The medical research company earned $46.20 million during the quarter, compared to analyst estimates of $39.63 million. InVitae had a negative net margin of 182.73% and a negative return on equity of 77.82%. InVitae's revenue was down 14.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.54) EPS.
View InVitae's earnings history.

7 Wall Street analysts have issued 12 month price targets for InVitae's stock. Their forecasts range from $20.00 to $48.00. On average, they anticipate InVitae's stock price to reach $36.75 in the next twelve months. This suggests that the stock has a possible downside of 20.2%.
View analysts' price targets for InVitae.

Some companies that are related to InVitae include Laboratory Co. of America (LH), Quest Diagnostics (DGX), Guardant Health (GH), Natera (NTRA), ELEKTA AB/ADR (EKTAY), Burning Rock Biotech (BNR), CareDx (CDNA), Veracyte (VCYT), Castle Biosciences (CSTL), Genetron (GTH), Personalis (PSNL), RadNet (RDNT), Fulgent Genetics (FLGT), ALX Oncology (RNLX) and Progenity (PROG).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other InVitae investors own include NVIDIA (NVDA), Square (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), salesforce.com (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

(NVTA) raised $76 million in an initial public offering (IPO) on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

InVitae's stock is owned by many different retail and institutional investors. Top institutional shareholders include State of Michigan Retirement System (0.06%), Concorde Asset Management LLC (0.02%), Focused Wealth Management Inc (0.02%), Sterling Investment Advisors Ltd. (0.02%), RFG Advisory LLC (0.02%) and Avitas Wealth Management LLC (0.01%). Company insiders that own InVitae stock include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Katherine Stueland, Patty Dumond, Randal W Scott, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida.
View institutional ownership trends for InVitae.

NVTA stock was sold by a variety of institutional investors in the last quarter, including Avitas Wealth Management LLC, Focused Wealth Management Inc, and Integrated Investment Consultants LLC. Company insiders that have sold InVitae company stock in the last year include E Lee Bendekgey, Eric Aguiar, Katherine Stueland, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer, and Thomas Brida.
View insider buying and selling activity for InVitae.

NVTA stock was bought by a variety of institutional investors in the last quarter, including State of Michigan Retirement System, Concorde Asset Management LLC, Sterling Investment Advisors Ltd., Carnegie Capital Asset Management LLC, NEXT Financial Group Inc, RFG Advisory LLC, Pacer Advisors Inc., and Steel Peak Wealth Management LLC.
View insider buying and selling activity for InVitae.

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVTA stock can currently be purchased for approximately $46.08.

InVitae has a market capitalization of $6.07 billion and generates $216.82 million in revenue each year. The medical research company earns $-241,960,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. InVitae employs 1,300 workers across the globe.

The official website for InVitae is www.invitae.com.

InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]